| Definition and characterization of a region of 1p36. 3 consistently deleted in neuroblastoma PS White, PM Thompson, T Gotoh, ER Okawa, J Igarashi, M Kok, C Winter, ... Oncogene 24 (16), 2684, 2005 | 220 | 2005 |
| CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system PM Thompson, T Gotoh, M Kok, PS White, GM Brodeur Oncogene 22 (7), 1002, 2003 | 214 | 2003 |
| Targeting immune checkpoints in breast cancer: an update of early results C Solinas, A Gombos, S Latifyan, M Piccart-Gebhart, M Kok, L Buisseret ESMO open 2 (5), e000255, 2017 | 147 | 2017 |
| A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice JB Foote, M Kok, JM Leatherman, TD Armstrong, BC Marcinkowski, ... Cancer immunology research, canimm. 0284.2016, 2017 | 142 | 2017 |
| Oestrogen receptor–co‐factor–chromatin specificity in the transcriptional regulation of breast cancer W Zwart, V Theodorou, M Kok, S Canisius, S Linn, JS Carroll The EMBO journal 30 (23), 4764-4776, 2011 | 142 | 2011 |
| Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer P Roepman, HM Horlings, O Krijgsman, M Kok, JM Bueno-de-Mesquita, ... Clinical Cancer Research, 1078-0432. CCR-09-0449, 2009 | 120 | 2009 |
| Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer C Holm, M Kok, R Michalides, R Fles, RHT Koornstra, J Wesseling, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009 | 87 | 2009 |
| Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen M Kok, SC Linn, RK Van Laar, MPHM Jansen, TM Van den Berg, ... Breast cancer research and treatment 113 (2), 275-283, 2009 | 83 | 2009 |
| PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer M Kok, W Zwart, C Holm, R Fles, M Hauptmann, LJ Van’t Veer, ... Breast cancer research and treatment 125 (1), 1-12, 2011 | 76 | 2011 |
| Estrogen receptor-α phosphorylation at serine-118 and tamoxifen response in breast cancer M Kok, C Holm-Wigerup, M Hauptmann, R Michalides, O Stål, S Linn, ... Journal of the National Cancer Institute 101 (24), 1725-1729, 2009 | 72 | 2009 |
| Immuno-oncology-101: overview of major concepts and translational perspectives B Allard, S Aspeslagh, S Garaud, FA Dupont, C Solinas, M Kok, B Routy, ... Seminars in cancer biology, 2018 | 71 | 2018 |
| Targeting the programmed cell death-1 pathway in breast and ovarian cancer LA Emens, M Kok, LS Ojalvo Current Opinion in Obstetrics and Gynecology 28 (2), 142-147, 2016 | 69 | 2016 |
| Decreased expression of ABAT and STC2 hallmarks ER‐positive inflammatory breast cancer and endocrine therapy resistance in advanced disease MPHM Jansen, L Sas, AM Sieuwerts, C Van Cauwenberghe, ... Molecular oncology 9 (6), 1218-1233, 2015 | 66 | 2015 |
| The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients RHN Van Schaik, M Kok, FCGJ Sweep, M Van Vliet, M Van Fessem, ... Pharmacogenomics 12 (8), 1137-1146, 2011 | 65 | 2011 |
| Mammosphere‐derived gene set predicts outcome in patients with ER‐positive breast cancer M Kok, RH Koornstra, TC Margarido, R Fles, NJ Armstrong, SC Linn, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009 | 57 | 2009 |
| Neoadjuvant therapy for breast cancer: established concepts and emerging strategies TG Steenbruggen, MS van Ramshorst, M Kok, SC Linn, CH Smorenburg, ... Drugs 77 (12), 1313-1336, 2017 | 56 | 2017 |
| Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data. M Kok, L Voorwerk, H Horlings, K Sikorska, K van der Vijver, M Slagter, ... Journal of Clinical Oncology 36 (15_suppl), 1012-1012, 2018 | 48 | 2018 |
| LBA14Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial M Kok, HM Horlings, K van De Vijver, T Wiersma, N Russell, L Voorwerk, ... Annals of Oncology 28 (suppl_5), 2017 | 33 | 2017 |
| Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes? MC Agahozo, D Hammerl, R Debets, M Kok, CHM Deurzen Modern Pathology, 1, 2018 | 32 | 2018 |
| Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma M Kok, JM Bonfrer, CM Korse, D de Jong, MJ Kersten Tumor biology 24 (1), 53-60, 2003 | 31 | 2003 |
